An experimental drug called BIIB094 reduced a key protein linked to Parkinson's disease by up to 59% in a first-in-human trial. The drug was safe and well-tolerated by 82 participants across two study segments.
← News
Science Breakthroughs Science Breakthroughs Knowledge
Experimental drug cuts Parkinson's-linked protein up to 60% in early trial
Up To 59% % Protein reduction
82 Trial participants
First-In-Human Study phase
None Reported Serious adverse events